NEUROCRINE BIOSCIENCES INC Quarterly Interest Expense in USD from Q2 2016 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Neurocrine Biosciences Inc quarterly/annual Interest Expense history and growth rate from Q2 2016 to Q1 2024.
  • Neurocrine Biosciences Inc Interest Expense for the quarter ending March 31, 2024 was $1.1M, unchanged year-over-year.
  • Neurocrine Biosciences Inc Interest Expense for the twelve months ending March 31, 2024 was $4.6M, a 17.9% decline year-over-year.
  • Neurocrine Biosciences Inc annual Interest Expense for 2023 was $4.6M, a 35.2% decline from 2022.
  • Neurocrine Biosciences Inc annual Interest Expense for 2022 was $7.1M, a 72.5% decline from 2021.
  • Neurocrine Biosciences Inc annual Interest Expense for 2021 was $25.8M, a 21.3% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $4.6M $1.1M $0 0% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $4.6M $1.1M $0 0% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-09
Q3 2023 $4.6M $1.1M -$100K -8.33% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-31
Q2 2023 $4.7M $1.3M -$900K -40.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-01
Q1 2023 $5.6M $1.1M -$1.5M -57.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $7.1M $1.1M -$5.5M -83.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-09
Q3 2022 $12.6M $1.2M -$5.4M -81.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-31
Q2 2022 $18M $2.2M -$4M -64.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $22M $2.6M -$3.8M -59.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $25.8M $6.6M -$1.2M -15.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-09
Q3 2021 $27M $6.6M -$1.9M -22.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $28.9M $6.2M -$2.1M -25.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $31M $6.4M -$1.8M -22% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $32.8M $7.8M -$400K -4.88% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-09
Q3 2020 $33.2M $8.5M +$500K +6.25% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-01
Q2 2020 $32.7M $8.3M +$400K +5.06% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $32.3M $8.2M +$300K +3.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $32M $8.2M +$467K +6.04% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-11
Q3 2019 $31.5M $8M +$328K +4.28% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $31.2M $7.9M +$309K +4.07% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
Q1 2019 $30.9M $7.9M +$396K +5.28% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $30.5M $7.73M +$314K +4.23% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-05
Q3 2018 $30.2M $7.67M +$335K +4.57% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $29.9M $7.59M +$2.82M +59.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-29
Q1 2018 $27M $7.5M +$7.5M Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $19.5M $7.42M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-07
Q3 2017 $7.34M +$7.34M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $4.77M +$4.77M Apr 1, 2017 Jun 30, 2017 10-Q 2018-07-31
Q1 2017 $0 Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-30
Q3 2016 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-01
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.